Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23290798 | 1.00 | SMN1; SMN2 (0.36) | SMN1; SMN2KDM4ELMNACYP2C19TSHR | |
| SCHEMBL22341005 | 0.90 | SMN1; SMN2 (0.33) | SMN1; SMN2KDM4ELMNACYP2C19 | |
| SCHEMBL22296005 | 0.90 | SMN1; SMN2 (0.33) | SMN1; SMN2KDM4ELMNACYP2C19 | |
| SCHEMBL24249016 | 0.90 | SMN1; SMN2 (0.33) | SMN1; SMN2KDM4ELMNACYP2C19 | |
| SCHEMBL16414228 | 0.90 | SMN1; SMN2 (0.33) | SMN1; SMN2KDM4ELMNACYP2C19 | |
| Oxalic Acid SCHEMBL23290975 | 0.89 | FFAR3 (0.32) | SMN1; SMN2 | |
| Oxalic Acid SCHEMBL23290977 | 0.89 | FFAR3 (0.32) | SMN1; SMN2 | |
| Oxalic Acid SCHEMBL31109890 | 0.89 | FFAR3 (0.32) | SMN1; SMN2 | |
| SCHEMBL22295920 | 0.80 | SMN1; SMN2 (0.37) | SMN1; SMN2KDM4ELMNACYP2C19TSHR | |
| SCHEMBL31267847 | 0.79 | KDM4E (0.36) | KDM4ELMNACYP2C19TSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612397-B2 | Methods and compositions for modulating splicing | SKYHAWK THERAPEUTICS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| EP-4724441-A1 | ISOINDOLINONE AND DIHYDROPYRROLOPRIDINONE COMPOUNDS AND USES THEREOF | Revir Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | disclosed |
| US-20250101016-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2025-03-27 | — | — | US | disclosed |
| CN-119528905-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2025-02-28 | — | — | CN | disclosed |
| CN-119320388-A | Methods and compositions for modulating splicing | 斯基霍克疗法公司 | 2025-01-17 | — | — | CN | disclosed |
| WO-2024251211-A1 | COMPOSITIONS, METHODS, AND SYSTEMS FOR MODULATING SPLICING OF MSH3 | REVIR THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| WO-2024251212-A1 | ISOINDOLINONE AND DIHYDROPYRROLOPRIDINONE COMPOUNDS AND USES THEREOF | REVIR THERAPEUTICS, INC. (US) | 2024-12-12 | — | — | WO | disclosed |
| US-12139499-B2 | Heteroaryl compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2024-11-12 | — | — | US | disclosed |
| EP-3814360-B1 | HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2024-10-02 | — | — | EP | disclosed |
| EP-3814345-B1 | HETEROARYL COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2024-09-25 | — | — | EP | disclosed |
| US-20200277289-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2020-09-03 | — | — | US | disclosed |
| WO-2020163248-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| WO-2020163544-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2020-08-13 | — | — | WO | disclosed |
| US-20200247799-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2020-08-06 | — | — | US | disclosed |
| US-20200247799-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2020-08-06 | — | — | US | disclosed |
| EP-3689863-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| US-20200224199-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2020-07-16 | — | — | US | disclosed |
| US-20200224199-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. | 2020-07-16 | — | — | US | disclosed |
| EP-3661509-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | Skyhawk Therapeutics, Inc. (US) | 2020-06-10 | — | — | EP | disclosed |
| WO-2019028440-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | SKYHAWK THERAPEUTICS, INC. (US) | 2019-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250101016-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SF3B5 | SMN1; SMN2 124/4885KDM4E 2544/4885LMNA 246/4885 |
| US-12612397-B2 | Methods and compositions for modulating splicing | SF3B1, SF3B2, SF1 | SMN1; SMN2 187/4885KDM4E 2812/4885LMNA 404/4885 |
| US-20200247799-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | SMN1; SMN2 123/4885KDM4E 2530/4885LMNA 218/4885 |
| US-12139499-B2 | Heteroaryl compounds for treating Huntington's disease | HTT, HYPK, HDAC6 | SMN1; SMN2 224/4885KDM4E 3075/4885LMNA 2395/4885 |
| US-20200277289-A1 | METHODS AND COMPOSITIONS FOR MODULATING SPLICING | RBM17, SF3B1, SNRPA1 | SMN1; SMN2 123/4885KDM4E 2530/4885LMNA 218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.